首页> 外文期刊>The Lancet >Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
【24h】

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.

机译:36个发展中国家和中等收入国家的药品价格,可获得性和可负担性:二次分析。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: WHO and Health Action International (HAI) have developed a standardised method for surveying medicine prices, availability, affordability, and price components in low-income and middle-income countries. Here, we present a secondary analysis of medicine availability in 45 national and subnational surveys done using the WHO/HAI methodology. METHODS: Data from 45 WHO/HAI surveys in 36 countries were adjusted for inflation or deflation and purchasing power parity. International reference prices from open international procurements for generic products were used as comparators. Results are presented for 15 medicines included in at least 80% of surveys and four individual medicines. FINDINGS: Average public sector availability of generic medicines ranged from 29.4% to 54.4% across WHO regions. Median government procurement prices for 15 generic medicines were 1.11 times corresponding international reference prices, although purchasing efficiency ranged from 0.09 to 5.37 times international reference prices. Low procurement prices did not always translate into low patient prices. Private sector patients paid 9-25 times international reference prices for lowest-priced generic products and over 20 times international reference prices for originator products across WHO regions. Treatments for acute and chronic illness were largely unaffordable in many countries. In the private sector, wholesale mark-ups ranged from 2% to 380%, whereas retail mark-ups ranged from 10% to 552%. In countries where value added tax was applied to medicines, the amount charged varied from 4% to 15%. INTERPRETATION: Overall, public and private sector prices for originator and generic medicines were substantially higher than would be expected if purchasing and distribution were efficient and mark-ups were reasonable. Policy options such as promoting generic medicines and alternative financing mechanisms are needed to increase availability, reduce prices, and improve affordability.
机译:背景:世卫组织和国际卫生行动组织(HAI)已开发出一种标准化方法,用于调查低收入和中等收入国家的药品价格,可获得性,可负担性和价格成分。在这里,我们介绍了使用WHO / HAI方法进行的45项国家和地区以下的药物可获得性的二级分析。方法:调整了来自36个国家的45个WHO / HAI调查的数据,以进行通货膨胀或通货紧缩以及购买力平价的调整。来自通用产品国际公开采购的国际参考价格被用作比较对象。列出了至少80%的调查中包含的15种药物和四种单独药物的结果。结果:在世卫组织各地区,公共部门仿制药的平均可获得率在29.4%至54.4%之间。 15种仿制药的政府采购价格中位数是相应国际参考价格的1.11倍,尽管采购效率在国际参考价格的0.09到5.37倍之间。较低的采购价格并不总是转化为较低的患者价格。私营部门患者为世卫组织各区域中价格最低的仿制产品支付了9-25倍的国际参考价格,为原始产品支付了20倍的国际参考价格。在许多国家,急性和慢性疾病的治疗基本上是负担不起的。在私营部门,批发加价幅度为2%至380%,而零售加价幅度为10%至5​​52%。在对药品征收增值税的国家,收费金额从4%到15%不等。解释:总体而言,如果购买和分销有效且加价合理,那么公共和私营部门原药和仿制药的价格将大大高于预期。需要采取政策选择,例如推广非专利药品和替代性融资机制,以增加供应,降低价格和提高可负担性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号